News
$Humacyte (HUMA.US)$ Humacyte Reports Positive Results From ATEV Treatment of Vascular Trauma in Ukraine
MT Newswires· 5 mins ago
Humacyte (HUMA) on Tuesday reported positive long-term results from its humanitarian program in Ukraine using the investigational acellular tissue engineered vessel, or ATEV, to treat severe vascular injuries.
The long-term data from the V017 trial showed 87.1% primary and secondary patency at 12 months. No infections, amputations, or deaths related to the ATEV were reported, despite high-risk conditions and severe injuries, Humacyte said. One case of ATEV thrombosis occurred after six months, the company added.
MT Newswires· 5 mins ago
Humacyte (HUMA) on Tuesday reported positive long-term results from its humanitarian program in Ukraine using the investigational acellular tissue engineered vessel, or ATEV, to treat severe vascular injuries.
The long-term data from the V017 trial showed 87.1% primary and secondary patency at 12 months. No infections, amputations, or deaths related to the ATEV were reported, despite high-risk conditions and severe injuries, Humacyte said. One case of ATEV thrombosis occurred after six months, the company added.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
104983812 : why the stock price still dropping?
Trytosaveabit OP 104983812 : To me it looks like a bit of profit scalping and SS’s on pretty low volume?